Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage II… (NCT00979212) | Clinical Trial Compass
CompletedPhase 2
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
United States71 participantsStarted 2011-02
Plain-language summary
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without panitumumab in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see how well they work when given with or without panitumumab in treating patients with stage IIIA non-small cell lung cancer.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed\* non-small cell lung cancer (NSCLC), including any of the following histologies:
* Adenocarcinoma
* Adenosquamous
* Large cell carcinoma
* Squamous cell carcinoma
* Non-lobar and non-diffuse bronchoalveolar cell carcinoma
* NSCLC not otherwise specified NOTE: \*Documentation of NSCLC may originate from the mediastinal node biopsy or aspiration
* Stage IIIA (T1-T3) disease with a single primary lung parenchymal lesion AND positive ipsilateral mediastinal node or nodes (N2) with or without positive ipsilateral hilar nodes (N1)
* N2 nodes must be separate from primary tumor by either CT scan or surgical exploration
* Maximum nodal diameter of involved N2 nodes cannot exceed 3.0 cm
* N2 status must be pathologically confirmed to be positive by one of the following methods\*:
* Mediastinoscopy
* Mediastinotomy (Chamberlain procedure)
* Transesophageal needle biopsy using endoscopic ultrasound (EUS-TBNA)
* Endobronchial ultrasound biopsy using endoscopic ultrasound guidance (EBUS-TBNA)
* Thoracotomy
* Video-assisted thoracoscopy
* Transbronchial needle biopsy by Wang technique (TBNA)
* Fine-needle aspiration under CT guidance NOTE: \*PET positivity in the ipsilateral mediastinal lymph nodes is not sufficient to establish N2 nodal status
* Ipsilateral mediastinal nodes associated with right-sided tumor must be biopsied unless all of the following are true:
* Tumor is lef…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab.
Timeframe: From date of randomization to time of protocol surgery, approximately 12 weeks.